Tumour-suppressor proteins articles from across Nature Portfolio

Tumour-suppressor proteins act to alleviate the potential for cancer and tumour formation by modulating cell growth either through negative regulation of the cell cycle or by promoting apoptosis. Mutation or dysregulation of tumour-suppressor proteins can lead to unregulated cell growth and tumour development.

Latest Research and Reviews

News and Comment

  • News & Views |

    Increased tRNA abundance and amino acid coupling generally promote increased oncogenesis. By contrast, a new study shows that in breast cancer, the leucyl-tRNA synthetase LARS suppresses transformation and tumour development by increasing tRNA-LeuCAG translation of certain tumour suppressor mRNAs.

    • C. Theresa Vincent
    •  & Robert J. Schneider
    Nature Cell Biology 24, 287-289
  • News & Views |

    A genome-wide CRISPR screen finds CIP2A as a new synthetic lethal target for BRCA1- and BRCA2-deficient cells. Unlike PARP inhibition that increases replication-induced DNA double-strand breaks and radial chromosomes, depleting CIP2A or disrupting its interaction with TOPBP1 increases micronuclei and chromosomal missegregation, revealing a mitotic target for BRCA-mutated tumors.

    • Demis Menolfi
    •  & Shan Zha
    Nature Cancer 2, 1296-1297
  • Research Highlights |

    Two recent studies have found that both the adaptive immune system and inflammation can drive the selection of cells carrying mutations that facilitate tumour initiation.

    • Sarah Seton-Rogers
  • News & Views |

    FTO, an m6A RNA demethylase, is known mainly as an oncoprotein in various cancer types. FTO is now shown to act as a cancer suppressor in a subset of epithelial tumors through an interplay between epithelial-to-mesenchymal transition and Wnt signaling.

    • Albertas Navickas
    •  & Hani Goodarzi
    Nature Cancer 2, 579-580